However, BRCA2 mutant tumors treated with PARP inhibitors have shown drug resistance caused by frame deletions of the BRCA2, which partially restore its DNA repair function, thereby allowing cancer cells to survive [28]. This evidence concerns the gene BRCA2 and cancer.